Articles by tag: fda-priority-review

Asundexian FDA Priority Status: Stroke Prevention Without Bleeding

The drug asundexian (Bayer) received FDA priority status for preventing recurrent stroke. Risk reduction of 26% without increased bleeding. Details of the OCEANIC-STROKE study.